FLT3 and acute myeloid leukemia: Due to their importance in defining overall AML risk and, by extension, the need for alloSCT, eligibility for upfront treatment with midostaurin, and post-relapse treatment with gilteritinib, testing for FLT3 mutations has become an essential part of the workup for AML.